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Summary 
 
Snake venoms are mixtures of numerous proteinacious components that exert 
diverse functional activities on a variety of physiological targets. Because the toxic 
constituents found in venom vary from species to species, snakebite victims can 
present with a variety of life-threatening pathologies related to the neurotoxic, 
cytotoxic and haemotoxic effects of venom. Of the 1.8 million people envenomed by 
snakes every year up to 125,000 die, while hundreds of thousands survive only to 
suffer with life-changing long-term morbidity. Consequently, snakebite is one of the 
world’s most severe neglected tropical diseases. Many snake venoms exhibit strong 
haemotoxic properties by interfering with blood pressure, clotting factors and 
platelets, and by directly causing haemorrhage. In this review we provide an 
overview of the functional activities of haemotoxic venom proteins, the pathologies 
they cause in snakebite victims and how their exquisite selectivity and potency make 
them amenable for use as therapeutic and diagnostic tools relevant for human 
medicine. 
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Venomous snakes are a species-rich (~2,500) group of squamate reptiles that are 
widely distributed across most of the Earth’s land masses and many of its oceans 
(Greene, 1997). These snakes primarily use venom for facilitating prey capture, 
although when threatened or provoked they use venom defensively, as observed in 
cases of human snakebite. The snake venom system consists of a pair of venom 
secretory glands, found either side of the head on the upper jaw, that are connected 
to ducts which transmit venom from the gland to the base of modified teeth (fangs) 
used for injection (Kerkkamp et al, 2015). Despite much morphological variation 
observed in the venom system of these animals, particularly pertaining to the 
structure of venom glands and the morphology and dental location of fangs, 
developmental and molecular evidence suggests that these structures are 
homologous and that venom originated on one occasion in snake ancestors at least 
60 million years ago (Fry et al, 2008; Vonk et al, 2008; Vidal et al, 2009; Kerkkamp et 
al, 2015). 
 
Despite this common evolutionary origin, we find considerable variation in the toxic 
constituents found in the venom of different snake species (Chippaux et al, 1991; Fry 
et al, 2008). Venoms consist of complex mixtures of proteinacious components (circa 
50-200), which are commonly referred to as toxins. These toxins have evolved from a 
number of non-toxic housekeeping genes by a variety of processes, most commonly 
gene duplication followed by neofunctionalization under the action of positive 
selection, but also via alternative splicing, recombination and simple modification of 
expression (Cousin et al, 1998; Lynch, 2007; Casewell et al, 2011; Moura-da-Silva et 
al, 2011; Vonk et al, 2013). Over millions of years of evolutionary time these 
ancestral venom toxins have diversified further via subsequent gene duplication 
events, ultimately giving rise to related toxin isoforms that are encoded by the same 
multi-locus gene family, but which often have distinct and/or complimentary functional 
activities (Fry et al, 2003; Lynch, 2007; Casewell et al, 2011; Vonk et al, 2013). 
Crucially, the rapid rate at which snake venom toxins have evolved, and their 
lineage-specific gene duplication and loss events, result in different snake species 
having different venom toxins. Consequently, variation in venom composition is 
observed across all taxonomic levels of snakes, between families, genera, species 
and even over the lifetime of an individual (Chippaux et al, 1991; Durban et al, 2013; 
Casewell et al, 2014). A schematic overview of how variation in snake venom 
composition has evolved is presented in Figure 1. 
 
Ultimately, these variable toxin components underpin the functional bioactivity of 
venom. Snake venoms can be broadly classified as haemotoxic, neurotoxic or 
cytotoxic (World Health Organization, 2010a). Many species possess multi-functional 
venoms that contain toxins capable of inducing different toxicities and, while there 
are general rules as to what to expect from human envenomings by many species, 
there are also many exceptions. For example, the two major medically important 
snake families are the vipers (family Viperidae; e.g. rattlesnakes, adders, vipers) and 
the elapids (family Elapidae; e.g. cobras, mambas, coral snakes) (Figure 2). A 
simplified historical overview is that viper venoms are predominately haemorrhagic 
and elapid venoms neurotoxic. While this simplification holds for many species there 
are a number of examples of vipers causing neurotoxicity (Silva et al, 2016) and 
elapids causing bleeding disturbances (Berling et al, 2015). Consequently, venom 
variation is a crucial factor that significantly impacts upon snakebite pathology and 
the treatment of snakebite. 
 
 
Snakebite is a neglected tropical disease 
 
Venomous snakes bite up to 5.5 million people every year (Kasturiratne et al, 2008). 
These bites are responsible for causing as many as 1.8 million envenomings and 
125,000 deaths annually, with three to five times that number of people thought to 
suffer from long-term morbidity (Chippaux, 1998; Kasturiratne et al, 2008; Habib et al, 
2015). Consequently, snakebite is one of the world’s most lethal neglected tropical 
diseases. Despite this, snakebite receives little attention from global health agencies, 
charities or governments, perhaps best exemplified by the World Health Organization 
(WHO) currently omitting snakebite from their formal list of neglected tropical 
diseases (http://www.who.int/neglected_diseases/diseases/en/). Despite this, the 
snakebite community continues to lobby for greater recognition surrounding this 
issue (Williams, 2015; Arnold, 2016), and recent progress has led to the WHO 
formally considering recognising snakebite as a neglected tropical disease at the 
upcoming World Health Assembly in 2017 (Harrison & Gutiérrez, 2016). 
 
Snakebite predominately affects people living in the tropical and sub-tropical regions 
of the world. While venomous snakes inhabit every continent, the vast majority of 
deaths occur in sub-Saharan Africa and South and South-East Asia (Figure 3) 
(Kasturiratne et al, 2008). Males are bitten more often than females, and bites are 
most common in younger adults and children, with children and the elderly seemingly 
suffering the greatest risk of mortality (World Health Organization, 2010b). 
Fundamentally, snakebite most greatly affects the rural impoverished people of the 
tropics (Harrison et al, 2009). There is a significant association between snakebite-
induced mortality and (i) the human developmental index, (ii) the percentage of the 
labour force working in agriculture, (iii) the per capita government expenditure on 
health and (iv) the GDP per capita of a country (Harrison et al, 2009). In part these 
associations are due to the rural people of the tropics frequently encountering snakes 
due to working in their habitat, typically in agricultural areas, and therefore are bitten 
more frequently. But also because the health infrastructure and economic status of 
these countries is less developed, meaning that victims often cannot afford protective 
footwear (>80% of bites are below the limb (Chippaux, 2010)), they have to travel for 
many hours to receive treatment (if they seek healthcare at all), and treatments are 
often not available within their available health infrastructure or, if they are, are 
unaffordable to many. 
 
The only specific therapy available for treating snakebite is antivenom. Antivenom 
consists of polyclonal antibodies that are generated by immunising animals (horses 
or sheep) with small amounts of snake venom. The resulting antibodies are purified 
from serum or plasma and formulated into intact IgG or F(ab’)2- or Fab-fragment 
therapies, which are administered intravenously following snakebite. While 
antivenoms are effective therapies for neutralising the toxicity of snake venoms if 
delivered promptly, there are a number of deficiencies with these products. First is 
the issue of venom variation described earlier. The antibodies present in any 
antivenom are specific to those venoms that were used for immunisation. Whilst 
these antibodies might cross-react with and neutralise similar venom toxins present 
in different species than those used for immunisation, there will be a limit to their 
cross-efficacy, and this is often restricted to the same genus of snakes (Williams et 
al, 2011; Tan et al, 2016a, 2016b). Despite a number of recent reports suggesting 
that certain antivenoms might have greater paraspecificity than previously anticipated 
(e.g. Pla et al, 2014; Tan et al, 2015), there are also a number of reports describing 
the poor performance or failure of antivenoms at neutralising venom from snakes 
related to those used for immunisation (Casewell et al, 2010; Segura et al, 2010; Tan 
et al, 2016b). Limitations with the paraspecificity of antivenoms are best exemplified 
by reports from sub-Saharan Africa where geographically inappropriate products 
were used to treat snakebite in the Central African Republic and Ghana, resulting in 
increases in case fatality rates from 0.4% and 1.0% to 10.0% and 12.1% respectively 
(Visser et al, 2008; Alirol et al, 2015).  
 To try and circumvent these limitations, many manufacturers generate antivenoms by 
immunising animals with multiple different snake venoms. These products have the 
benefit of generating antibodies against a wider pool of antigens (i.e. the variety of 
toxins found in different snake venoms) and they also circumvent clinical challenges 
surrounding identifying the snake that has bitten a patient required to inform 
antivenom choice. However, the consequences of this approach are that the 
antivenom contains fewer specific antibodies to the single snake species that 
envenomed the patient, effectively making them more dilute. Therefore, larger 
therapeutic doses are required to effect cure (Abubakar et al, 2010). This in turn 
brings two challenges, a potential increased risk of adverse reactions as larger doses 
of foreign protein are delivered to human victims, and an increased treatment cost as 
more vials are required to effect cure. Considering that the incidence of adverse 
reactions reported after antivenom therapy can be as high as 55% (Deshpande et al, 
2013) and the average cost of a vial of antivenom varies from $100-250 in Africa for 
example, with upwards of 10-20 vials being required to effect cure (World Health 
Organization, 2010a), these characteristics are far from ideal. There is therefore an 
urgent need for the development of new, low-dose, low-cost and paraspecifically 
effective antivenoms for treating snakebite victims in the tropical regions of the world 
(Harrison et al, 2011).  
 
 
Snakebite causes a multitude of pathologies 
 
Because of the diversity of toxic components found in the venom of any one snake, 
the pathological consequences of envenoming can be diverse and multifactorial. 
Moreover, variables such as the location of the bite site and the amount of venom 
injected (which in turn can be highly variable (Alirol et al, 2010)) can contribute to the 
severity of clinical signs observed in snakebite victims. While pathology can be 
limited to local effects surrounding the bite site, such as pain, oedema and bruising, 
many envenomings also result in systemic pathology, which can be severe and lethal 
if untreated. Clinical patterns of envenoming can be broadly classified into three 
groups: neurotoxic, cytotoxic and haemotoxic, although myotoxicity can also present 
in certain cases (World Health Organization, 2010a). It is important to note that 
certain snake species are capable of causing combinations of these different 
toxicities, and there are also examples of the same snake species causing different 
pathologies in human patients across different parts of their range (Antonypillai et al, 
2011; Massey et al, 2012). 
 
Neurotoxic envenoming is characterised by descending neuromuscular paralysis, 
beginning with the eyes (ptosis), facial muscles and other muscles innervated by the 
cranial nerves, before progressing to respiratory and generalised flaccid paralysis 
(Warrell, 1995a, 1995b; Chippaux, 2010; World Health Organization, 2010a, 2010b). 
The toxins predominately responsible for neurotoxic venom effects are members of 
the diverse phospholipases A2 (PLA2) and three-finger toxin (3FTX) families (Fry et 
al, 2003; Lynch, 2007). These toxins are capable of acting on the pre- and/or post-
synaptic junction, where they can have a multitude of actions, from blocking 
potassium or sodium channels, to acting as nicotinic or muscarinic receptor 
antagonists (Fry et al, 2003; Lynch, 2007; Casewell et al, 2013). Ultimately, many 
snakes contain multiple different neurotoxins in their venom that perturb 
neurotransmission at the neuromuscular junction, resulting in paralysis. 
 
Snakebite victims suffering from cytotoxic envenoming are characterised by painful 
and progressive swelling at the bite site, developing into blistering and bruising, and 
are sometimes coupled with systemic effects, which include hypovolaemic shock 
(World Health Organization, 2010a, 2010b). Often, extensive local tissue damage 
develops (Figure 2), characterised by necrosis of the affected limb and requiring 
surgical debridement or amputation if left untreated. Hydrolytic enzymes such as 
snake venom metalloproteinases (SVMPs) and PLA2s, and non-enzymatic cytotoxic 
3FTXs have been implicated as the causative agents found in different snake 
venoms (Escalante et al, 2009; Rivel et al, 2016). Recently it was shown that the 
destruction of local tissue may also be promoted by snake venom inducing the 
formation of neutrophil extracellular traps (NETs), which in turn block blood vessels 
and contain the venom toxins to bite site, thereby promoting cytotoxic pathology 
(Katkar et al, 2016). 
 
For the remainder of this review we focus on haemotoxicity caused by snake 
venoms. Haemotoxicity is one of the most common clinical signs in victims of 
snakebite, particularly when viperid snakes are responsible for envenomings. Broadly 
speaking, haemotoxic venoms can have cardiovascular and/or haemostatic effects. 
Cardiovascular effects are perhaps best characterised by a dramatic fall in blood 
pressure and this can be caused by a number of different venom toxins. For 
example, SVMPs indirectly contribute to hypotension by increasing vascular 
permeability via the degradation of capillary basement membranes, resulting in 
leakage and reductions in blood pressure (Gutiérrez et al, 2016). Snakes can also 
directly induce vasodilatory effects via the injection of bradykinin potentiating 
peptides (BPPs) present in their venom, and this activity can be further enhanced by 
certain snake venom serine protease (SVSP) toxins exhibiting kallikrein-like 
functionalities, causing the release of bradykinins from plasma kininogens (Phillips et 
al, 2010; Camargo et al, 2012). Ultimately, these various venom toxins, whether 
acting alone or in combination, can cause shock in envenomed patients due to 
systemic hypotension (Figure 4A). 
 
Haemostatic effects caused by snake venoms are best characterised by local and 
systemic haemorrhage. Overt signs include bleeding from the gums, recently healed 
wounds, the bite site, the gastro-intestinal and/or genito-urinary tracts and/or 
haematemesis and haemoptysis (Figure 2) (Warrell, 1995a, 1995b; World Health 
Organization, 2010b). As described above, SVMP toxins increase the vascular 
permeability of blood vessels by degrading capillary basement membranes, resulting 
in extravasation (Gutiérrez et al, 2016), and therefore these toxins also exert 
haemorrhagic activities (Figure 4A).  While spontaneous systemic bleeding therefore 
contributes to deaths caused by shock (hypotension), snake venom is also 
responsible for causing fatalities via haemorrhage, particularly when intracranial 
bleeding occurs (Mosquera et al, 2003). 
 
Haemorrhage caused by snake venom is often complicated and exacerbated by 
patients presenting with blood clotting disturbances as the result of venom-induced 
consumption coagulopathy (VICC). VICC, a disseminated intravascular coagulation 
(DIC)-like syndrome, is characterised by low or undetectable levels of fibrinogen, 
resulting in incoagulable blood (Figure 2) (Isbister, 2010; Maduwage & Isbister, 
2014). However, unlike DIC, VICC does not usually result in systemic microthrombi 
and end-organ failure and it presents with a rapid onset and resolution (Isbister, 
2010). Although the majority of snakes known to cause VICC are vipers, certain 
elapid snakes from Australasia and colubrid and natricine snakes from Africa and 
Asia have also been reported to cause consumptive coagulopathies via the action of 
their procoagulant toxins (Maduwage & Isbister, 2014). These toxins are diverse and 
include SVMPs, snake venom serine proteases and toxic forms of Factor X and 
Factor V (Phillips et al, 2010; Rosing & Tans, 2010; Kini & Koh, 2016). The targets 
for these toxins are also varied, with many activating clotting factors found towards 
the end of the clotting cascade, such as Factor X and prothrombin, while others are 
fibrinogenolytic (Figure 4B) (Maduwage & Isbister, 2014; Kini & Koh, 2016). 
Consequently, in addition to the depletion of fibrinogen, patients suffering from VICC 
often exhibit other factor deficiencies due to their consumption, including Factor II, 
Factor V, Factor VIII and Factor X (Isbister et al, 2010, 2015; Maduwage & Isbister, 
2014). Although many of the countries where snakebite is abundant rely on simple 
bedside tests to detect incoagulable blood (e.g. the 20 minute whole blood clotting 
test), a number of studies have demonstrated that patients suffering from VICC 
present with a prolonged prothrombin time (PT), and an international normalised ratio 
and activated partial thromboplastin time (aPTT) that are either very high or exceed 
the upper limits of detection (Isbister et al, 2010, 2015). Finally, many snake venom 
toxins are known to act on platelets. C-type lectins, disintegrins and certain 
metalloproteinases, to name a few, are capable of either inducing the aggregation of 
platelets, for example by von Willebrand factor- or collagen-mediated activation, or 
inhibiting their aggregation, by potently blocking integrin receptors found on the 
surface of platelets, such as α2β3 (Rucavado et al, 2005; Chakrabarty & Chanda, 
2015; Kini & Koh, 2016). Both inhibition and activation (via hypoaggregation) result in 
these toxins contributing to venom-induced coagulopathies by depleting platelets, 
and this presents clinically as marked thrombocytopenia (Warrell, 1995a, 1995b; 
Rucavado et al, 2005).  
 
The consequences of venom-induced coagulopathies are an increased risk of 
serious and life-threatening haemorrhage, particularly when envenoming is the result 
of bites by snakes that also contain haemorrhagic SVMPs in their venom. Indeed, in 
many fatal cases involving intracranial haemorrhage, snakebite victims were found to 
also be suffering from clotting disorders (Mosquera et al, 2003; Berling et al, 2015). 
Consequently, coagulopathy has been described as the most common, important, 
systemic, clinical syndrome caused by snake envenoming (Maduwage & Isbister, 
2014). 
 
 
Haemotoxic snake venom components 
 
In this section we provide an overview of the snake venom toxin types that exhibit 
haemotoxic properties, with a particularly focus on the snake venom 
metalloproteinases and the snake venom serine proteases. We summarise the 
various haemotoxic activities of these toxins in Figure 4. Snake venom 
metalloproteinases (SVMPs) are a diverse enzymatic toxin family that are found in 
the venom of most advanced snakes, although they are most commonly key 
components in viperid species (Casewell et al, 2015). Having diversified extensively 
via gene duplication followed by the loss of functional domains (Casewell et al, 
2011), a single snake species can contain more than a dozen SVMPs in its venom, 
and these structural variants (classified as P-I, P-II and P-III SVMPs) can exhibit 
diverse functionalities (including being multi-functional), ranging from haemorrhagic, 
fibrinogenolytic, Factor X or prothrombin activating activities to inhibiting platelet 
aggregation (Fox & Serrano, 2005; Casewell et al, 2015). Many SVMPs are 
haemorrhagic, with the P-III class being broadly more haemorrhagic than the P-IIs, 
and P-IIs more so than the P-Is (Fox & Serrano, 2005; Gutiérrez et al, 2010). Such 
SVMPs ultimately affect the integrity of endothelial cells in blood vessels, causing 
them to swell and burst and thereby promoting extravasation. However, this action is 
not due to direct cytotoxic effects, but instead by SVMPs binding and hydrolysing 
structural components of the basement membrane of capillary vessels, such as type 
IV collagen and perlecan, that link the membrane to the extracellular matrix 
(Gutiérrez et al, 2016). This cleavage weakens the scaffold structure and 
subsequently haemodynamic forces (hydrostatic pressure and shear stress) induce a 
distention of the vessel wall, ultimately leading to rupture and haemorrhage 
(Gutiérrez et al, 2016).  
 
Many SVMPs, particularly P-Is, are fibrinogenolytic (Fox & Serrano, 2005). The 
majority of SVMPs actively cleave the α-chain of fibrinogen into fibrinopeptides, and 
while some of these proteins also exhibit a lower degree of activity on the β-chain, 
there are relatively few SVMPs that preferentially degrade the β-chain (Markland, 
1998). Ultimately, such degradation results in defibrination, which in turn contributes 
to coagulopathy and bleeding disturbances. Certain SVMPs have also been 
described as procoagulants by activating the clotting factors prothrombin or Factor X. 
Many of these toxins are derivations of P-III SVMPs, and they are often found 
natively complexed to other venom toxins like C-type lectins, although non-
complexed P-I SVMPs with prothrombin activating capabilities have also been 
described (Fox & Serrano, 2005; Modesto et al, 2005; Gutiérrez et al, 2010). Factor 
X activators have been isolated from a number of snake venoms, including from both 
vipers and elapids, and the most well studied of these is the P-III SVMP known as 
RVV-X from the Russell’s viper (Daboia russelli) (Siigur & Siigur, 2010). RVV-X 
cleaves Factor X in the same manner as that which happens during the physiological 
activation of this clotting factor, resulting in the release of the serine protease known 
as activated Factor X (Factor Xa), which in turn acts on prothrombin in conjunction 
with activated Factor V (Factor Va) (Siigur & Siigur, 2010). RVV-X requires the 
presence of Ca2+ for activation, as this induces a conformational change in Factor X 
that is a prerequisite for proteolysis by this SVMP (Siigur & Siigur, 2010). As 
described above, prothrombin is physiologically activated by the prothrombinase 
complex (Factor Xa and Factor Va), and this requires the presence of Ca2+ and 
phospholipases as cofactors. A number of SVMPs directly activate prothrombin to 
release thrombin, which in turn acts on fibrinogen to generate fibrin clotting. In doing 
so, these toxins (and also the Factor X activator RVV-X) contribute strongly to VICC, 
by consuming the limited amounts of clotting factors physiologically available via their 
continual activation. Some SVMP-based prothrombin activators are capable of 
functioning in the absence of cofactors, whereas others rely on the presence of 
calcium, and have thus been classified as either group A or group B prothrombin 
activators respectively (Rosing & Tans, 2010). Examples include the calcium-
independent activator ecarin, and the calcium-dependent SVMP carinactivase-1, 
both of which are found in the venom of the saw-scaled viper Echis carinatus (Rosing 
& Tans, 2010). 
 
Disintegrins are small (40-100 amino acid) cysteine-rich polypeptides that are derived 
from the proteolytic cleavage of P-II SVMPs or from genes solely encoding 
disintegrins (so called true or short-coding disintegrins) (Calvete et al, 2005). 
Disintegrins are structurally diverse and best known for their action as integrin 
receptor antagonists, with different toxins capable of selectively blocking different 
cell-surface integrins relevant to a variety of pathological conditions (e.g. α2β3 
integrins for acute coronary ischaemia and thrombosis; αvβ3 for tumour metastasis, 
osteoporosis and rheumatoid arthritis; α4β1, α7β1 and α9β1 for inflammation and 
autoimmune diseases, etc) (Calvete et al, 2010). The most relevant to this review are 
those disintegrins that bind to α2Bβ3 integrins (the glycoprotein IIb/IIIa “platelet 
fibrinogen” receptor), thereby preventing fibrinogen binding to platelets and inhibiting 
platelet aggregation (Calvete et al, 2005). These “RGD” motif-containing peptides 
have only been described from viperid snakes and it is not uncommon for such 
snakes to contain multiple different disintegrins in their venom (Calvete et al, 2010). 
In addition, some proteolytically processed P-III SVMPs, consisting of disintegrin-like 
domains coupled to cysteine-rich domains, also appear to inhibit platelets via 
interactions with α2β1 integrins; resulting in the inhibition of collagen-stimulated 
platelet aggregation (Shimokawa et al, 1997; Calvete et al, 2005). However, it 
remains unclear whether the disintegrin-like domains of these toxins are responsible 
for this activity. In summary, SVMPs and related toxins exhibit various functions that 
impair haemostasis, including inducing haemorrhage, depleting various clotting 
factors and inhibiting platelet function. Their diversity and abundance in many snake 
venoms make them one of the most important toxin families relevant to venom-
induced haemotoxicity. 
 
Snake venom serine proteases (SVSPs) are often referred to as thrombin-like 
enzymes (TLEs) due to many exhibiting fibrinogenolytic functional activities 
analogous to thrombin. The majority of these serine protease enzymes have been 
isolated from viperid snakes, and many are known to effectively degrade fibrinogen 
into fibrinopeptides via proteolytic cleavage (Phillips et al, 2010). However, in 
contrast to thrombin, which readily cleaves both the α and β chains of fibrinogen, 
TLEs are typically more selective and usually only cleave one of these chains. 
Similarly to the SVMPs, most TLEs characterised to date act on the α chain, although 
there are examples of SVSPs that only cleave the β chain and a few that act on both 
α and β chains (Pirkle, 1998; Phillips et al, 2010). This cleavage of fibrinogen results 
in the polymerisation of fibrin monomers, but because TLEs do not stimulate factor 
XIII to cross-link these polymers, as thrombin would, this results in unstable clots that 
are readily dissolved by plasmin (Phillips et al, 2010). Ultimately, the continual 
generation and destruction of fibrin thrombi results in a consumptive coagulopathy 
that depletes fibrinogen physiologically.  
 
TLEs also exhibit other functionalities relevant to haemostasis by mimicking 
thrombin, which is itself a multi-functional enzyme. For example, certain TLEs from 
the venom of the copperhead (Agkistrodon contortrix contortrix) and the horned 
desert viper (Cerastes cerastes) activate Factor XIII and either Factor V or Factor X, 
respectively (Marrakchi et al, 1995; Amiconi et al, 2000). Others induce the release 
and aggregation of platelets, potentially via their interaction with the protease-
activated receptor-1 (PAR-1) or the membrane glycoprotein receptor GpIb, both of 
which are found on the surface of platelets (Phillips et al, 2010). Certain TLE SVSPs 
have been described that exhibit kallikrein-like functionalities by inducing the release 
of kinins, such as Lys-bradykinin, by acting directly on plasma kininogens (Oyama & 
Takahashi, 2003). Finally, some TLEs are also capable of activating plasminogen by 
cleaving their peptide bonds, resulting in the release of plasmin and the degradation 
of fibrin, and therefore seem likely to contribute to consumption coaguloapathies via 
different mechanisms (Zhang et al, 1995). 
 
There are two other types of serine protease toxins found in snake venom, and these 
are structurally and genetically distinct from the TLEs described above. Both of these 
serine proteases are only found in the venom of certain Australasian elapid snakes 
and they mimic activated versions of the clotting factors Factor X and Factor V, 
having evolved via the duplication of genes encoding these physiological blood 
clotting components (Reza et al. 2007; Reza & Kini, 2010). Consequently, these 
toxins activate prothrombin and are classified as group C and group D prothrombin 
activators (Rosing & Tans, 2010). Group C prothrombin activators, such as pseutarin 
C from the venom of the Eastern brown snake (Pseudonaja textilis) and oscutarin 
from the coastal taipan (Oxyuranus scutellatus), are large multi-subunit proteases 
consisting of both Factor Xa-like and Factor Va-like subunits and therefore effectively 
mimic the prothrombinase complex (Rosing & Tans, 2010). These toxins are 
abundant in brown snake and taipan venom and they rely on Ca2+ and phospholipids 
to effectively activate prothrombin, resulting in the production of thrombin and the 
consumption of clotting factors, causing VICC (Reza et al, 2007; Isbister et al, 2010; 
Rosing & Tans, 2010; Maduwage & Isbister, 2014). Many more Australasian snakes 
have the less potent group D prothrombin activators in their venom. Similar to those 
described above, these toxins require Ca2+ and phospholipids as cofactors, but unlike 
the group C activators they also require the presence of Factor Va, as these toxins 
do not consist of multiple subunits and therefore do not mimic the prothrombinase 
complex, instead mimicking only activated Factor X (Reza & Kini, 2010; Rosing & 
Tans, 2010). As with group C activators, these toxins effectively cleave prothrombin 
into thrombin and initiate continual activation of the blood clotting cascade (Reza & 
Kini, 2010). 
 
In addition to the SVMPs and SVSPs, there are many other snake venom toxin types 
that play a role in perturbing haemostasis. For example, certain kunitz-type serine 
protease inhibitors found in venom (e.g. Textilinin-1 and -2, also from the Eastern 
brown snake P. textilis) potently inhibit plasmin (and also thrombin), and thereby 
acting as antifibrinolytic agents (Flight et al, 2005, 2009). Bradykinin-potentiating 
peptides (BPPs), so called because they potentiate the effects of bradykinin, have 
been isolated from numerous pit viper species. These peptides have been 
demonstrated to inhibit angiotensin converting enzyme (ACE), thereby preventing the 
conversion of the hormone angiotensin I into the vasoconstrictor angiotensin II, 
resulting in a reduction in systemic blood pressure (Xu et al, 2015). Consequently, 
BPPs can contribute to hypotension observed following envenoming, and their effect 
is likely exacerbated by haemorrhagic SVMPs and SVSPs that exhibit kallikrein-like 
functions (Figure 4A). Furthermore, certain snake venom PLA2s have also been 
demonstrated to induce hypotensive effects in vivo, and some of these functionally 
diverse proteins are also known to exert anticoagulant effects by inhibiting platelet 
aggregation (Andrião-Escarso et al, 2002; Teixeira et al, 2011). Another toxin family 
known to affect platelet function are the C-type lectin-like proteins (CTLs). In fact, 
various CTLs have been described that exhibit a number of functional activities 
relating to haemostasis, including binding to Factor IX and X to inhibit blood 
coagulation, inhibiting the binding of thrombin to fibrinogen, and inhibiting or 
activating platelet aggregation by interacting with von Willebrand factor or collagen 
receptors (Lu et al, 2007; Arlinghaus et al, 2015). 
 
 
Pharmaceutical utility of snake venom haemotoxins 
 
Venom components are gaining renewed interest as potential sources of new 
pharmacological compounds relevant for human therapeutics and diagnostics. Such 
developments are not limited to snake venoms, with toxins isolated from the toxic 
secretions of cone snails, sea anemones, spiders and scorpions exhibiting 
bioactivities relevant for the management of chronic pain, stroke and various 
autoimmune diseases (King, 2011). Nonetheless, snake venoms represent the most 
comprehensively studied of all venomous lineages and, consequently, have the most 
numerous lead compounds associated with them. Because of the specificity of many 
snake venom toxins, and their activity in targeting specific components related to 
cardiovascular processes, almost all of the snake venom derived pharmaceuticals 
available today have therapeutic or diagnostic indications relevant to haemostasis. 
 
The first blockbuster drug developed from a venom toxin was Captopril (Capoten). 
Captropril was developed following the identification of an ACE inhibitor in the venom 
of the jararaca pit viper (Bothrops jararaca). This bradykinin potentiating peptide 
inhibits the conversion of angiotensin I into angiotensin II, thereby reducing systemic 
blood pressure by preventing the production of a crucial vasoconstrictor (Ferreira et 
al, 1970). Consequently, captopril was developed in the 1970’s as a synthetic 
analogue of this toxin and indicated for use as a hypotensive drug. It achieved FDA 
approval in the early 1980’s, subsequently becoming Squibb’s first billion dollar drug, 
and the success of this product resulted in the development of many analogues (e.g. 
enalapril, lisinopril, perindopril and ramipril) being introduced into the market (Smith & 
Vane, 2003; McCleary et al, 2015). 
 Other snake venom toxin types have been successfully translated into human 
therapeutics. Both Tirofiban (Aggrastat) and Eptifibatide (Integrillin) are derived from 
disintegrin molecules found in the venoms of the saw-scaled viper (Echis carinatus) 
and the dusky pygmy rattlesnake (Sistrurus miliarius barbouri) respectively. Both 
these disintegrins exhibit potent inhibition of the integrin receptor α2β3, thereby 
preventing the aggregation of platelets. Both toxins were developed synthetically; as 
a non-peptidic molecule in the case of Tirofiban and as a cyclic heptapeptide analog 
for Eptifibatide (McCleary et al, 2015). Consequently, these anticoagulant 
therapeutics function by effectively inhibiting platelet aggregation and they are 
indicated for use in patients suffering from unstable angina and myocardial 
infarctions (Peerlinck et al, 1993; Scarborough, 1999). 
 
Batroxobin is a drug developed from a serine protease toxin (SVSP) isolated from the 
venom of the Brazilian lancehead viper (Bothrops moojeni). As with many SVSPs, 
this enzymatic toxin exhibits potent specificity for fibrinogen, in this case effectively 
releasing fibrinopeptide A via cleavage of the α-chain of fibrinogen (McCleary et al, 
2015). Such thrombin-like SVSP enzymes also benefit from not being inhibited by 
classical serine protease inhibitors, whether endogenous (e.g. antithrombin III) or 
exogenous (e.g. hirudin) (Hutton & Warrell, 1993; McCleary et al, 2015). Although the 
fibrinogenolytic activity of batroxobin initially promotes the formation of clots, its is an 
anticoagulant drug of relevance for treating thrombotic disorders, as the degradation 
of fibrinogen leads to defibrination and, secondarily and indirectly, this in turn induces 
the release of tissue plasminogen activator, which converts plasminogen into plasmin 
and promotes the degradation of clots (McCleary et al, 2015). Specific indications for 
batroxobin include the treatment of ischemic stroke, angina, myocardial and cerebral 
infraction and wound management after surgical interventions (Xu et al, 2007; 
Phillips et al, 2010).  
 
Similarly, Ancrod (Arvin/Arwin/Viprinex), isolated from the venom of the Malayan pit 
viper (Calloselasma rhodostoma), is another well known SVSP that readily degrades 
fibrinogen, resulting in defibrination. Ancrod was also developed for use as an 
anticoagulant and indicated for the treatment of ischaemic stroke, myocardial 
infarction and deep-vein thrombosis (Marsh & Williams, 2005), and showed potential 
benefit to patients suffering from heparin-associated thrombocytopenia and 
thrombosis syndrome (Illig & Ouriel, 1996). However, over the course of many years 
equivocal results from clinical trials have since resulted in Ancrod being suspended 
from use (McCleary et al, 2015). Similarly, another defibrinating toxin, this time a 
synthetic form of an SVMP found in the venom of the copperhead (Agkistrodon 
contortrix), failed to meet desired endpoints in phase III clinical trials, despite positive 
results in phase I and II trials (Moll et al, 2006; Han et al, 2010). Consequently, the 
manufacturer withdrew this therapeutic, known as Alfimeprase, from further 
development.  
 
Despite these setbacks, pharmaceutical manufacturers continue to pursue the 
development of venom components as future therapeutic agents for treating 
haemostatic disturbances. For example, other fibrinogenolytic SVSPs are currently in 
development, including “hemocogulase agkistrodon” isolated from the Chinese 
moccasin (Deinagkistrodon acutus) and “crotalase” from the Eastern diamondback 
rattlesnake (Crotalus adamanteus) (McCleary et al, 2015). Both of these serine 
protease toxins are in early development as anticoagulant therapeutics, with 
predicted indications including decreasing clotting times during surgical procedures 
(McCleary et al, 2015). Various venom toxins isolated from the venom of the Eastern 
brown snake (P. textilis) are also currently in development as haemostatic agents. 
The kunitz-type serine protease inhibitor Textilinin-1 inhibits plasmin, and has little to 
no effect on other serine proteases. This toxin therefore exhibits desirable 
characteristics as an anti-fibrinolytic drug and, under the moniker Q8008, is being 
developed for use for reducing blood loss associated with complex surgeries (Earl et 
al, 2010). In addition, the activated Factor X- and Factor V-like toxins found in P. 
textilis venom are also being translated into novel therapeutics to control bleeding. 
The Factor Xa-like protein is being developed under the name of Haempatch to 
control bleeding at sites of trauma or surgery, whereas the Factor Va-like protein, 
CoVase, is being assessed for its utility for combating non-compressible 
haemorrhage (Earl et al, 2010; McCleary et al, 2015).  
 
Haemotoxic components isolated from snake venoms are also commonly used for 
diagnostic purposes, particularly relating to blood clotting tests. For example, the 
SVMP toxin ecarin, a calcium independent prothrombin activator from the saw-scaled 
viper (E. carinatus), has been used for over two decades as a standard in the ecarin 
clotting time test. This assay is used for the quantification of direct thrombin 
inhibitors, and has proven particularly useful as a means to monitor levels of drugs 
such as hirudin during anticoagulant therapy (Nowak, 2004). Ecarin is also used in a 
diagnostic test for lupus anticoagulants, alongside textarin from the Eastern brown 
snake (P. textilis) (Stocker et al, 1994). Using the variable specificity of these two 
procoagulant venom toxins, of which ecarin acts independently of cofactors whereas 
textarin requires phospholipids, calcium and factor V, to compare patient clotting 
times circumvents issues with lupus antibodies interfering with phospholipids, which 
other coagulation tests typically rely upon (Triplett et al, 1993). One such assay, the 
dilute Russell’s viper venom time test (dRVVT test), also harnesses the procoagulant 
effect of snake venom as a clotting standard. In this case coagulation is primarily the 
result of the SVMP Factor X activator RVV-X and the SVSP Factor V activator RVV-
V and, consequently, Russell’s viper venom has been used to assay blood clotting 
factors V and X, as well as lupus anticoagulants (Marsh & Williams, 2005). Finally, a 
protein C activating SVSP, protac, isolated from venom of the copperhead 
(Agkistrodon contortrix) (Stocker et al, 1987) is used in protein C and protein S 
diagnostic assays to test for activated protein C resistance, whereas the SVSP 
reptilase, from the lancehead viper (Bothrops atrox), is used to screen for heparin 
contamination in plasma, as its fibrinogenolytic activity is unaffected by heparin (Funk 
et al, 1971). 
 
 
Summary 
 
Snake venom haemotoxins exhibit diverse functionalities that can result in 
haemorrhagic, coagulopathic and/or hypotensive pathology in snakebite victims. The 
functional diversity of these toxins and their relative abundance in many venoms, 
particularly those of vipers, mean that such haemotoxins are likely to act in a 
synergistic manner to perturb haemostasis. While providing an effective means for 
the snakes to catch their prey, for example by causing ischaemic or haemorrhagic 
events or shock due to systemic hypotension, the consequences for human 
snakebite victims can also be lethal. Consequently, furthering our understanding of 
the bioactivity of venom haemotoxins and their variation from one snake species to 
the next is essential for the design of next-generation antivenom therapies. In 
addition, venom haemotoxins remain highly relevant for use as investigational 
ligands for understanding vertebrate physiology due to their high levels of selectivity 
and potency, and also for the development of new therapeutic and diagnostic 
pharmaceuticals relevant for human medicine. 
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Figures and legends 
 
 
 
Figure 1. A simplified schematic demonstrating how snake venoms have evolved 
into variable toxin mixtures over evolutionary timescales. Ovals represent venom 
glands in different snakes (hypothetical ancestors or modern day species) and 
coloured circles represent different toxin types. Non-venomous ancestors had no 
toxins in their venom gland (or expressed them at very low levels), but early 
venomous snake ancestors recruited a number of toxin types into their venom. Over 
evolutionary time, as lineages diverged, different toxin types became utilised in the 
venom of certain snakes, and these toxin types diversified differentially via the 
process of gene duplication and loss, resulting in variation in venom composition 
observed between different groups of snakes. 
 
 
 
 
Figure 2. Representative venomous snakes and the pathology they cause in sub-
Saharan Africa. A) Examples of medically-important venomous snakes. From left: 
Joger’s saw-scaled viper (Echis jogeri) from Senegal; the puff adder (Bitis arietans) 
from Kenya; the Mozambique spitting cobra (Naja mossambica) from South Africa. 
Photographs courtesy of Wolfgang Wüster. B) Pathology caused by venomous 
snakes. Clockwise from top left: A dedicated ward for snakebite victims in Kaltungo, 
Nigeria; extensive local tissue damage following a bite by an unknown cytotoxic 
snake (likely the spitting cobra Naja nigricollis) in north-east Nigeria; blood filled 
blisters following a bite by the cytotoxic puff adder (Bitis arietans) in the area of Kilifi, 
Kenya; local and systemic haemorrhage (two images) facilitated by venom-induced 
consumption coagulopathy following a bite by a saw-scaled viper (Echis ocellatus) in 
north-east Nigeria. A patient receiving a slow intravenous infusion of antivenom 
following a bite by a saw-scaled viper (E. ocellatus) in north-east Nigeria. 
Photographs courtesy of the Alistair Reid Venom Research Unit, Liverpool School of 
Tropical Medicine. 
  
  
 
Figure 3. Estimates of annual deaths caused by snakebite in different global burden 
of disease (GBD) regions. Conservative estimates are displayed by different colour 
shadings on the map and upper estimates are annotated for each major region 
where the number of snakebite deaths is greater than 1,000. The world map image is 
reproduced from Kasturiratne et al. (2008) under the Creative Commons Attribution 
License and the overlaid upper estimates of snakebite death are taken from the 
same publication. 
 
 
 
 
Figure 4. A schematic overview of the physiological targets of haemotoxic snake 
venom toxins. A) The targets for venom toxins that cause cardiovascular effects, 
which present clinically as hypotension. B) The targets for venom toxins that cause 
haemostatic effects, which present as coagulopathy. Each physiological target is 
indicated by a red circle and the venom toxin type(s) that target these sites are listed. 
FV – Factor V; FVa – activated Factor V; FX – Factor X; FXa – activated Factor X; FII 
– prothrombin. 
 
 
 
 
 
 
